Closing Figures Unveiled: Guardant Health Inc (GH) Drop -3.15, Closes at $95.05

Kiel Thompson

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

Guardant Health Inc (NASDAQ: GH) closed the day trading at $95.05 down -3.15% from the previous closing price of $98.14. In other words, the price has decreased by -$3.15 from its previous closing price. On the day, 9.8 million shares were traded. GH stock price reached its highest trading level at $95.24 during the session, while it also had its lowest trading level at $88.88.

On April 10, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $55.Mizuho initiated its Outperform rating on April 10, 2025, with a $55 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 17 ’25 when Tariq Musa sold 116 shares for $66.95 per share. The transaction valued at 7,766 led to the insider holds 7,725 shares of the business.

POTTER MYRTLE S sold 26 shares of GH for $1,741 on Oct 17 ’25. The Director now owns 18,324 shares after completing the transaction at $66.95 per share. On Oct 17 ’25, another insider, Tariq Musa, who serves as the Director of the company, bought 116 shares for $66.95 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 11980206080 and an Enterprise Value of 12836070400. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.27. Its current Enterprise Value per Revenue stands at 14.222 whereas that against EBITDA is -31.915.

Stock Price History:

The Beta on a monthly basis for GH is 1.59, which has changed by 2.4326687 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $100.22, while it has fallen to a 52-week low of $23.27. The 50-Day Moving Average of the stock is 43.54%, while the 200-Day Moving Average is calculated to be 85.22%.

Shares Statistics:

Over the past 3-months, GH traded about 2.68M shares per day on average, while over the past 10 days, GH traded about 3602540 shares per day. A total of 125.01M shares are outstanding, with a floating share count of 120.39M. Insiders hold about 4.49% of the company’s shares, while institutions hold 99.54% stake in the company. Shares short for GH as of 1760486400 were 8273789 with a Short Ratio of 3.09, compared to 1757894400 on 8744644. Therefore, it implies a Short% of Shares Outstanding of 8273789 and a Short% of Float of 6.950000000000001.

Earnings Estimates

A detailed examination of Guardant Health Inc (GH) is currently in progress, with 14.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.29 and low estimates of -$0.6.

Analysts are recommending an EPS of between -$0.64 and -$1.91 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$1.4, with 16.0 analysts recommending between -$0.89 and -$2.31.

Revenue Estimates

18 analysts predict $267.76M in revenue for. The current quarter. It ranges from a high estimate of $270M to a low estimate of $264.82M. As of. The current estimate, Guardant Health Inc’s year-ago sales were $201.81MFor the next quarter, 18 analysts are estimating revenue of $269.72M. There is a high estimate of $284.1M for the next quarter, whereas the lowest estimate is $247.8M.

A total of 21 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $970.1M, while the lowest revenue estimate was $965.57M, resulting in an average revenue estimate of $968.57M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.22B in the next fiscal year. The high estimate is $1.32B and the low estimate is $1.09B.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.